Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl] amino-1-oxo-2-isoindolynl]-glutaric acid] in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 3, 2004, Pages 894-902

  Desjardins, John ^a   Emerson, David L ^a   Colagiovanni, Dorothy B ^a   Abbott, Elizabeth ^a   Brown, Eric N ^a   Drolet, Daniel W ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; FLUOROURACIL; GS 7904; GW 1843; LIPOSOME; OSI 7904L; THYMIDYLATE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; INDOLES; LIPOSOMES; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; QUINAZOLINES; THYMIDYLATE SYNTHASE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442715094     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.064725     Document Type: Article

References (25)

1. Banks SD, Waters KA, Barrett LL, Dickerson S, Pendergast W, and Smith GK (1994) Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations. Cancer Chemother Pharmacol 33:455-459.
2. Beutel G, Glen H, Schoffsski P, Chick J, Versluis J, Gill SC, Adams L, and Twelves C (2003) Phase I study of liposomal thymidylate synthase inhibitor (TSI) OSI-7904L in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22:140.
3. Boytos CM, Ferone R, Jones WA, Rudolph SK, Franklin SL, and Houle CD (1995) In vivo antitumor activity of 1843U89 against experimental liver metastases in the nude mouse. Proc Am Assoc Cancer Res 36:376.
4. Danenberg PV, Malli H, and Swenson S (1999) Thymidylate synthase inhibitors. Semin Oncol 26:621-631.
5. Dev IK, Dallas WS, Ferone R, Hanlon M, McKee DD, and Yates BB (1994) Mode of binding of folate analogs to thymidylate synthase. Evidence for two asymmetric but interactive substrate binding sites. J Biol Chem 269:1873-1882.
6. Duch DS, Banks S, Dev IK, Diekerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, et al. (1993) Biochemical and cellular pharmacology of 1843U89 a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53:810-818.
7. Fielding RM (2001) Relationship of pharmacokinetically-calculated volumes of distribution to the physiologic distribution of liposomal drugs in tissues: implications for the characterisation of liposomal formulations. Pharm Res (NY) 18:238-242.
8. Fielding RM, Moon-McDermott L, Lewis RO, and Horner MJ (1999) Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob Agents Chemother 43:503-509.
9. Gabizon A (1989) Liposomes as a drug delivery system in cancer chemotherapy, in Drug Carrier Systems (Roerdink FHD and Kroon AM eds) pp 185-211, John Wiley & Sons, Inc., New York.
10. Gabizon A, Price DC, Huberty J, Bresalier RS, and Papahadjopoulos D (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 50:6371-6378.
11. Hanlon MH and Ferone R (1996) In vitro uptake, anabolism and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res 56:3301-3306.
12. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Duschinsky R, Schnitzer RJ, Pleven E, and Griesbach L (1957) Fluorinated pyrimidines a new class of tumor-inhibitory compounds. Nature (Lond) 179:663-666.
13. Heidelberger C, Griesbach L, Cruz O, Schnitzer RJ, and Grunberg E (1958) Fluorinated pyrimidines VI. Effects of 5-fluorouridine and 5-fluor-2′ -deoxyuridine on transplanted tumors. Proc Soc Exp Biol Med 97:470-475.
14. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, and Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
15. Jackman AL, Taylor GA, Calvert AH, and Harrap KR (1984) Modulation of antimetabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol 33:3269-3275.
16. Maruyama K, Unezaki S, Yuda T, Ishida O, Takahashi N, Suginaka A, Huang L, and Iwatsuru M (1994) Enhanced delivery and antitumor effect of doxorubicin encapsulated in long-circulating liposomes. J Liposome Res 4:143-165.
17. Mayer LD, Masin D, Nayar R, Boman NL, and Bally MB (1995) Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumors. Br J Cancer 71:482-488.
18. Newman MS, Colbern GT, Working PK, Engbers C, and Amantea MA (1999) Comparative pharmacokineties, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7.
19. Ostro MJ and Cullis PR (1989) Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 46:1576-1587.
20. Peters GJ and Köhne CH (1999) Fluoropyrimidines as antifolate drugs, in Antifolate Drugs in Cancer Chemotherapy (Jackman AL ed) pp 101-145, Humana Press, Inc., Totowa, New Jersey.
21. Schwartz G, Johnson T, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker J, Von Hoff D, and Rowinsky E (2001) A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advance solid malignancies. Clin Cancer Res 7:1901-1911.
22. Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, and Wilson HR (1995) Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55:6117-6125.
23. Smith GK, Bigley JW, Dev IK, Duch DS, Ferone R, and Pendergast W (1999) GW1843 a potent, noncompetitive thymidylate synthase inhibitor-preclinical and preliminary clinical studies, in Antifolate Drugs in Cancer Chemotherapy (Jackman AL ed) pp 203-227, Humana Press, Inc., Totowa, New Jersey.
24. Webb MS, Logan P, Kanter PM, St.-Onge G, Gelmon K, Harasym T, Mayer LD, and Bally MB (1998) Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42:461-470.
25. Zee-Cheng RKY and Cheng CC (1989) Delivery of anticancer drugs. Methods Find Exp Clin Pharmacol 11:439-529.